Schroder Investment Management Group Reduces Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Schroder Investment Management Group cut its holdings in Progyny, Inc. (NASDAQ:PGNYFree Report) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 937,720 shares of the company’s stock after selling 48,499 shares during the period. Schroder Investment Management Group owned 0.98% of Progyny worth $34,864,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC raised its position in shares of Progyny by 12.4% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 35,611 shares of the company’s stock valued at $1,324,000 after purchasing an additional 3,940 shares during the period. Eagle Asset Management Inc. grew its stake in Progyny by 102.7% during the fourth quarter. Eagle Asset Management Inc. now owns 649,897 shares of the company’s stock valued at $24,163,000 after acquiring an additional 329,288 shares in the last quarter. Olympiad Research LP grew its stake in Progyny by 22.1% during the fourth quarter. Olympiad Research LP now owns 7,958 shares of the company’s stock valued at $296,000 after acquiring an additional 1,443 shares in the last quarter. Millrace Asset Group Inc. purchased a new position in Progyny during the fourth quarter valued at $2,408,000. Finally, Hsbc Holdings PLC purchased a new position in Progyny during the fourth quarter valued at $1,095,000. 94.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $48.00 target price on shares of Progyny in a research note on Thursday, May 16th. SVB Leerink began coverage on shares of Progyny in a research note on Monday, February 26th. They issued an “outperform” rating and a $49.00 price objective for the company. Canaccord Genuity Group dropped their price objective on shares of Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a research note on Monday, February 26th. Finally, Barclays dropped their price objective on shares of Progyny from $48.00 to $30.00 and set an “overweight” rating for the company in a research note on Monday, May 13th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.11.

View Our Latest Analysis on PGNY

Insider Activity

In related news, President Michael E. Sturmer sold 6,395 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.60, for a total transaction of $240,452.00. Following the completion of the transaction, the president now owns 384,553 shares in the company, valued at approximately $14,459,192.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Chairman David J. Schlanger sold 5,826 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $37.74, for a total transaction of $219,873.24. Following the completion of the transaction, the chairman now owns 86,312 shares in the company, valued at approximately $3,257,414.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Michael E. Sturmer sold 6,395 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $37.60, for a total transaction of $240,452.00. Following the sale, the president now directly owns 384,553 shares in the company, valued at approximately $14,459,192.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,770 shares of company stock worth $3,853,985. 12.30% of the stock is currently owned by corporate insiders.

Progyny Stock Performance

NASDAQ:PGNY opened at $27.60 on Monday. Progyny, Inc. has a one year low of $23.90 and a one year high of $44.95. The firm has a market cap of $2.63 billion, a P/E ratio of 45.25, a P/E/G ratio of 1.89 and a beta of 1.46. The firm has a 50-day simple moving average of $30.90 and a 200-day simple moving average of $35.05.

Progyny (NASDAQ:PGNYGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. Progyny had a net margin of 5.53% and a return on equity of 11.61%. The business had revenue of $278.08 million during the quarter, compared to analyst estimates of $289.41 million. During the same quarter in the previous year, the business posted $0.18 EPS. The company’s quarterly revenue was up 7.6% compared to the same quarter last year. On average, research analysts predict that Progyny, Inc. will post 0.69 EPS for the current fiscal year.

Progyny Profile

(Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.